JRT (drug)

JRT
	Above: JRT molecular structure; Below: 3D representation of a (+)-JRT molecule
Clinical data
Other names	Isoindole-LSD; Isotryptamine-LSD
Drug class	Serotonin receptor modulator; Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen; Psychoplastogen
ATC code	None;
Identifiers
	IUPAC name (7S)-N,N-diethyl-6-methyl-6,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2,10,12(16),13-pentaene-4-carboxamide;
PubChem CID	166076087;
Chemical and physical data
Formula	C20H25N3O
Molar mass	323.440 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)C1CN([C@@H]2CN3C=CC4=C3C(=CC=C4)C2=C1)C;
	InChI InChI=1S/C20H25N3O/c1-4-22(5-2)20(24)15-11-17-16-8-6-7-14-9-10-23(19(14)16)13-18(17)21(3)12-15/h6-11,15,18H,4-5,12-13H2,1-3H3/t15?,18-/m1/s1; Key:ZYTVEPYZRGXVRK-KPMSDPLLSA-N;

JRT, also known as isoindole-LSD or isotryptamine-LSD, is a serotonin receptor modulator, psychoplastogen, and serotonergic psychedelic related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the embedded tryptamine structure within the ergoline ring system of LSD has been replaced with an isotryptamine structure.

The drug acts as a non-selective serotonin receptor modulator, including as a partial agonist of the serotonin 5-HT_2A receptor and as an agonist or antagonist of various other serotonin receptors. The drug has psychedelic-like, psychoplastogenic, antipsychotic-like, antidepressant-like, and pro-cognitive effects in animals and preclinical studies, whilst lacking apparent pro-psychotic-like effects. It has significant but reduced psychedelic-like effects compared to LSD in animals. The drug is a racemic mixture of (+)- and (–)- enantiomers, with (+)-JRT being the active and employed form.

JRT was first described in the scientific literature by 2022 and was described in greater detail in 2025. It was developed by David E. Olson and colleagues in association with Delix Therapeutics. The drug is being investigated as a possible treatment for schizophrenia.